UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 46

of 'Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer'

46
TI
Efficacy and Safety of Lorlatinib in ALK+ Non-Small Cell Lung Cancer (NSCLC) Patients (pts) with>1 Prior ALK Tyrosine Kinase Inhibitor (TKI): A Phase 1/2 Study
AU
Shaw AT, Ou S-H I, Felip E, Bauer TM
SO
J Clin Oncol. 2017;35S; abstract #9006
 
AD